What this ad does well
Leading with a drug name people already know is a strong launch move: the viewer doesn't have to learn what Wegovy is, only that there's a new way to start it. "New way" signals news, which earns attention from people who've already been considering GLP-1s. The pill between two fingers shows the oral format, and the qualify button sets an honest expectation for a prescription product.
What's missing
"New" tells the viewer something changed but not why it matters to her. The image doesn't say it's a lower dose or that it's built for people with less weight to lose, which is the whole point of the plan. If you make a launch ad like this, finish the sentence: put the who-it's-for line under the headline so the news comes with a reason, and add the first-month price near the button.
Beat by beat
- Image
Two fingers hold a white pill on olive green, with short plan facts and a "See if you qualify" button over a weight loss by hers bar.It shows the oral format and puts the eligibility step in view.
- Headline
"A new way to start Wegovy" on the image, with "Get Started Today" as the ad headline.It borrows the familiarity of a known drug name and frames the plan as news.
- Copy
The copy calls it a new way to start Wegovy with Hers, built for those with less weight to lose, with a $39 first month and "Free Shipping" in the description.It explains who the new plan is for and what it costs to begin.
The offer
The copy lists a membership at $39 for the first month, then $149/month, and its fine print says the price covers the membership only, doesn't include or guarantee a prescription, and that microdosing is off-label and lower doses are unstudied for weight loss. Hers frames it as a low-commitment way in rather than a discount. The ad's description line adds free shipping.
Where it sends people
The click lands on a dedicated lower-dose plan page, one of 9 ads in the Fluid library that point there, which sits between a focused landing page and a quiz. Under a "Wegovy Pill Microdosing Plan now available with Hers" bar, the hero headline reads "Built for modest goals" beside a short tap-to-answer intake ("What brings you here today?" with answers like losing a few stubborn pounds), followed by more soft questions, a "We've got range" row of treatment cards with starting prices, a membership checklist and an FAQ that includes why to start on a lower dose. The page's announcement bar repeats the news framing (the microdosing plan is now available with Hers), so the "new" in this ad is confirmed at the very top of the page.
The page it sends people to: How Hers gives its lower-dose Wegovy plan its own landing page
Hers's landing page for the Wegovy Pill Microdosing Plan leads with "Built for modest goals", then asks three soft prompts about why the visitor is here, how they want to approach it and how they want to feel, before a plan carousel, membership perks and a plan-specific FAQ. 9 ads in the Fluid library send people here, all launch ads.
How the page is built
- 01
Announcement bar and headerA green bar announces that the Wegovy Pill Microdosing Plan is now available with Hers, above a logo-only header, so the launch news is the first thing a visitor reads.
- 02
Hero with first promptA portrait with a line-graph overlay and a pill product card carries the modest-goals headline, beside a three-step indicator and the question "What brings you here today?" with three answers in the visitor's words.
- 03
Approach promptA second question asks how the visitor wants to approach weight loss, answering "will this fit how I want to do it?" with three pill choices.
- 04
Feeling promptA third question asks how the visitor wants to feel, closing the intake on the outcome they picture rather than a medical detail.
- 05
Plan carouselAn FSA and HSA eligible tag and a Get started today button sit above cards for the Wegovy Pill, the Microdosing Plan, the Wegovy Pen and Ozempic, each with a "from" monthly price, a membership-required note and a safety link.
- 06
Pricing fine printSmall print under the cards explains that prices cover medication only and that a separate membership is required, answering the cost question in full for anyone who reads it.
- 07
MembershipA four-photo collage over five check rows (treatment plan, provider messaging, member community, partner discounts, smart scale) answers "what comes with the membership?"
- 08
FAQSeven accordions cover the membership, its cost, the difference from the full-dose pill, why start lower, switching later, state availability and insurance, with a Get started today button beside them.
The first fixes we would make
- There's no proof on the page: no member stories, no provider explaining who the lower-dose plan is for, nothing beyond the collage photos. Add a short provider note or a few member stories from people with modest goals right after the plan carousel, attributed and with the usual disclaimers, so the visitor sees someone like them before they commit.
- The page's own FAQ asks how the Microdosing Plan differs from the Wegovy Pill, which tells you visitors need that comparison, yet the carousel shows the two as similar-looking cards. Put a small side-by-side table of the two plans (dose approach, monthly price, who each is for) above the FAQ, so the answer is visible instead of hidden in an accordion.
Read the full breakdown of this page
Three hooks you could test
- Sell the outcome. “A new way to start, made for smaller goals.”
- Make the product the whole scene. “The treatment you've heard of, in a smaller first step.”
- Call out the habit you're replacing. “You don't have to start at full strength anymore.”
What to borrow for your brand
- When launching a variation of something people know, lead with the known name and the word "new," then explain the difference underneath.
- Repeat the launch news in the landing page's announcement bar so the visitor sees it confirmed the moment she arrives.
- Pair "new" with the audience it's built for, so the news comes with a reason to care.
One of 125 Hers ads in the Fluid Inspiration Library, captured from the Meta Ad Library on Oct 22, 2026. We record that an ad ran publicly, not how it performed.